They found that there was no association between the time to initiation of NAC and patient survival for HER2-positive cancer (HR = 0.91; 95% CI = 0.74–1.12) and triple-negative cancer (HR = 1.10; 95% CI = 0.97–1.24). The gene discussed is ERBB2; the disease is cancer.